NCT03720990View on ClinicalTrials.gov

Smith-Lemli-Opitz Syndrome and Cholic Acid

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 27, 2021

Primary Completion Date

August 30, 2022

Study Completion Date

September 30, 2023

Conditions
Smith-Lemli-Opitz Syndrome
Interventions
DRUG

Cholic Acid

Participants will be treated with cholic acid for 8 weeks

Trial Locations (2)

68198

University of Nebraska Medical Center, Omaha

80045

Colorado Children's Hospital, Aurora

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

collaborator

University of Pittsburgh

OTHER

lead

University of Nebraska

OTHER

NCT03720990 - Smith-Lemli-Opitz Syndrome and Cholic Acid | Biotech Hunter | Biotech Hunter